acquired
Stage
1
Investors
About
Rewrite Therapeutics is a UC Berkeley spinout developing CRISPR-guided DNA polymerization technology that enables genome editing without double-strand breaks, particularly targeting challenges in editing non-dividing cell types.
Explore Rewrite Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.